TABLE 2.
Pharmacokinetic parameters from plasma dataa
| Patient | Cmax (mg/liter) | Cmin (mg/liter) | AUC0-8 (mg·h/liter) | AUMC0-8 (mg·h2/liter) | MRT (h) | CLtot (liters/h) | CLrenal (liters/h) | CLnon-CVVHF (liters/h) | Kel (h−1) | t1/2 (h) | Vz (liters/kg) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 50.4 | 14.3 | 169.1 | 31,538.3 | 186.5 | 5.9 | 0.007 | 2.0 | 0.11 | 6.53 | 0.21 |
| 2 | 58.3 | 5.70 | 139.8 | 20,905.9 | 149.6 | 7.2 | 0.003 | 3.2 | 0.26 | 2.72 | 0.76 |
| 3 | 54.8 | 7.57 | 162.2 | 26,012.7 | 160.4 | 6.2 | 0.000 | 2.7 | 0.20 | 3.46 | 0.46 |
| 4 | 61.9 | 4.21 | 174.3 | 38,821.5 | 222.7 | 5.7 | 0.000 | 2.3 | 0.10 | 6.90 | 0.21 |
| 5 | 74.7 | 21.5 | 397.5 | 112,647.4 | 283.4 | 2.5 | 0.000 | 0.0 | 0.09 | 8.07 | 0.35 |
| 6 | 42.7 | 7.2 | 163.8 | 38,016.8 | 232.1 | 6.1 | 0.024 | 3.1 | 0.16 | 4.30 | 0.34 |
| 7 | 74.8 | 16.9 | 281.0 | 49,981.5 | 177.9 | 3.6 | 0.000 | 0.2 | 0.16 | 4.47 | 0.46 |
| 8 | 49.4 | 8.73 | 159.9 | 27,308.6 | 170.7 | 6.3 | 0.018 | 2.5 | 0.26 | 2.68 | 0.40 |
| 9 | 42.4 | 5.93 | 115.3 | 18,919.1 | 164.1 | 8.7 | 0.011 | 4.6 | 0.35 | 2.00 | 0.81 |
| 10 | 66.9 | 7.63 | 199.4 | 31,218.3 | 156.6 | 5.0 | 0.008 | 1.5 | 0.16 | 4.35 | 0.31 |
| Median | 56.6 | 7.6 | 166.5 | 31,378.3 | 174.3 | 6.0 | 0.005 | 2.4 | 0.16 | 4.32 | 0.37 |
| 25th percentile | 49.7 | 6.2 | 160.5 | 26,336.7 | 161.3 | 5.2 | 0.000 | 1.6 | 0.12 | 2.90 | 0.32 |
| 75th percentile | 65.7 | 12.9 | 193.1 | 38,620.3 | 213.7 | 6.2 | 0.010 | 3.0 | 0.24 | 6.02 | 0.46 |
a
Abbreviations: Cmax, observed maximum concentration during sampling period; Cmin, observed minimum concentration during sampling period; AUC0-8, area under the concentration-time curve during 8-hour dosing period; AUMC0-8, area under the moment curve during 8-hour dosing period; MRT, mean residence time; CLtot, total clearance; CLrenal, renal clearance; CLnon-CVVHF, clearance not mediated by CVVHF; Kel, elimination rate constant; t1/2, elimination half-life; Vz, apparent volume of distribution during terminal phase.